The aim of this study is to investigate whether intensive, personalized IFX dosing by using a
pharmacokinetics driven dashboard system during the induction phase in patients with acute
severe UC leads to increased treatment success (as defined by clinical and endoscopic
response at week 6) as compared to the standard dosing.
Phase:
Phase 4
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)